The mechanism behind the pronounced effect of estrogen on CRP is most likely an effect on gene expression in the liver. Strong support for this assumption that this effect is mediated by estrogen itself and not by a factor stimulated by estrogen comes from the observations that the effect is dose-dependent, is seen in both women and men, and occurs only after oral treatment. It is not clear whether the effect of estrogen on gene expression is mediated by transcriptional activation or RNA stabilization. No hormone response elements have been discovered in the promoter of the CRP gene, but one study has shown that estrogen can stimulate the transcription factor C/EBP-␤, which is involved in CRP transcription (9 ).
N-Terminal Pro-B-Type Natriuretic Peptide Concentrations Are Markedly Higher in the Umbilical Cord Blood of Newborns than in Their Mothers
Bernd Puschendorf, 1 and Rudolf Sommer 4 ( 1 Biocenter, Division of Clinical Biochemistry, and 2 Department of Internal Medicine, Clinical Division of Cardiology, Innsbruck Medical University, Austria; 3 Gynecologic and Paediatric Hospital Linz, Linz, Austria; 4 Institute of Medical and Chemical Laboratory Diagnostics, Gynecologic and Paediatric Hospital Linz, Linz, Austria; * address correspondence to this author at: Biocenter, Division of Clinical Biochemistry, Innsbruck Medical University, Fritz-Pregl-Strassse 3, A-6020 Innsbruck, Austria; fax 43-512-507-2876, e-mail Angelika. Lercher@uibk.ac.at) Natriuretic peptides are well-established markers in adult heart failure patients (1 ) and may also be useful for identifying neonates or children with cardiac diseases. Recent studies demonstrated high N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations in healthy neonates with a subsequent rapid decrease within several days (2, 3 ) . However, in the transition from fetal to neonatal life, the physiologic role of natriuretic peptides is not fully understood. Furthermore, it is currently not known whether natriuretic peptides in the fetal circulation derive from the fetus itself or whether there is a placental exchange of maternal natriuretic peptides. The aim of this study, therefore, was to determine the NTproBNP concentrations in healthy neonates and to compare their concentrations with the values for their respective mothers to indirectly demonstrate a possible placental NT-proBNP exchange.
From 100 neonates delivered consecutively between The study is consistent with the Declaration of Helsinki. Venous umbilical cord blood and peripheral venous blood from the mothers had been drawn for routine blood analyses such as blood grouping. NT-proBNP concentrations in the sample remnants were measured by a sandwich electrochemiluminescence immunoassay (Elecsys 1010; Roche) as described previously (4 ) . The Wilcoxon signed-rank test was used to assess differences in fetal and maternal NT-proBNP concentrations, the MannWhitney test was used for gender comparison, and Spearman rank correlation coefficients were calculated. A P value Ͻ0.05 was considered statistically significant. Median (25th-75th percentiles) NT-proBNP concentrations [553.4 (413.5-832.9) ng/L] were on average 11.6-fold higher (6.9-to 32-fold) in the cord blood than in the blood samples from the respective mothers [45.5 (22.9 -76.8) ng/L; P Յ0.0001; Fig. 1 ]. The NT-proBNP concentrations for the respective mothers and newborns did not correlate (r ϭ Ϫ0.11; P ϭ 0.49). There was also no significant difference (P ϭ 0.76) in NT-proBNP concentrations between sexes in the neonates.
In this study, we, for the first time, compared NTproBNP concentrations in a significant number of mothers and their newborn infants immediately after delivery, using a commercially available automated assay. To date, only one small study has compared fetal [mean (SE), 1052.0 (181.5) ng/L] and maternal NT-proBNP concentrations [569.3 (74.0) ng/L] by a RIA (5 ); the results indicated that NT-proBNP concentrations in healthy fetuses in the 21st week of gestation are twice as high as in maternal blood. The use of different nonstandardized immunoassays, which detect different epitopes and fragments of NT-proBNP, may partly explain the differences between our present study and the previous study. Different gestational ages and the stress of delivery may also influence the secretion patterns of NT-proBNP. Furthermore, the mothers in the study of Walther et al. (5 ) were not well characterized. In the present study, all mothers were healthy and consequently had low NT-proBNP concentrations.
Umbilical venous cord blood NT-proBNP concentrations of neonates are representative of NT-proBNP concentrations in newborns; Mir et al. (2 ) reported similar NT-proBNP concentrations in the umbilical venous cord blood and peripheral venous blood on the day of delivery. Arterial and venous umbilical cord blood was shown to have similar NT-proBNP concentrations as well (6 ) . Therefore, the high concentrations of natriuretic peptides immediately after delivery may be explained in part by the perinatal circulatory changes from fetus to neonate. After delivery, three important circulatory pathways, the ductus venosus, the foramen ovale, and the ductus arteriosus, are closed, which leads to an increase in pulmonary blood flow in response to lung expansion. Consequently, right ventricular volume and pressure load are increased at birth as well, which may contribute to the peaking of natriuretic peptide concentrations immediately after delivery. Because there was no significant correlation between cord blood and maternal NT-proBNP concentrations, we suggest that there is no placental exchange of NT-proBNP and that increased concentrations in neonates derive from the neonates themselves.
The NT-proBNP tests were provided by Roche Diagnostics (Austria) free of charge. The company had no influence on study design, data analysis or interpretation, and the content of the manuscript. (2 ) , and renal osteodystrophy (3 ) . The effects of specimen type, collection temperature, and storage temperature on the in vitro stability of PTH differ by method and platform (4 -10 ) . Characterization of preanalytical effects unique to each method, platform, and patient population is important to prevent potential clinical misclassification.
The Diagnostics Product Corporation (DPC) IMMU-LITE 2000 intact PTH assay is a solid-phase two-site chemiluminescent immunoassay with a monoclonal mouse capture antibody and a polyclonal goat signal antibody conjugated to alkaline phosphatase. The effects of preanalytical factors on this assay have been partially investigated. Underfilling of EDTA-plasma tubes decreased measured PTH in samples from both healthy persons and those with chronic kidney disease (CKD) (11 ) . Storage of SST serum samples for 3 days at room temperature decreased measured PTH in SST serum samples, an effect not seen with EDTA plasma (6 ) . Results from EDTA plasma paradoxically increased after storage at 4°C (12 ). Despite evidence that PTH is more stable in EDTA-anticoagulated specimens (5-7, 9, 10 ) , the manufacturer describes an instability associated with EDTAplasma samples and therefore recommends cold (2-8°C) collection, centrifugation, and storage until analysis (13 ).
At our institution, PTH is most frequently measured for management of CKD and helps direct therapies, including calcium, vitamin D, bisphosphonates, and parathyroidectomy. Preanalytical influences on PTH assays may be atypical in CKD because samples contain increased concentrations of N-terminal truncated PTH fragments that cross-react with intact PTH assays (14 ). Accordingly, we have investigated preanalytical variables in a dialysis-dependent CKD population. The study was approved by the St. Paul's Hospital ethics committee.
Five predialysis samples were obtained from 31 CKD patients between 0800 and 0930 h. Two specimens were drawn into Becton Dickinson (BD) 6-mL dipotassium EDTA Vacutainer TM plastic tubes: the first was immediately placed on ice and then centrifuged at 4°C (EDTA cold ), whereas the second was collected and centrifuged at room temperature (EDTA RT ). The three remaining samples were drawn into 5-mL BD Vacutainer TM SST ® plastic tubes containing gel and clot activator. The first (SST cold ) and second (SST RT ) serum specimens were collected in the same manner as their EDTA counterparts. A third specimen (SST spuncold ) was collected in accordance with the manufacturer's indication that SST specimens can be collected at room temperature but require cold centrifugation and subsequent refrigeration (15 ). All tubes were filled completely. Each of the five tubes was separated into four aliquots. Aliquots from the EDTA cold , SST cold , and SST spuncold tubes were maintained at 4°C until analysis, whereas aliquots from the EDTA RT and SST RT tubes remained at room temperature. Each aliquot was analyzed at baseline (within 3 h) and after 24, 48, and 72 h, according to the manufacturer's protocols (reagent lot 121).
Using SPSS (Ver. 13.0), we performed two separate 2 ϫ 2 ϫ 4 within-subject repeated-measures ANOVA analyses: the first was (EDTA/SST) ϫ (room temperature/ cold) ϫ (time), and the second was (EDTA/SST) ϫ (room temperature/spuncold) ϫ (time). We explored the interactions between sample type and temperature and sample type and time and found them to be significant; we therefore considered the effects of temperature and time separately. Bonferroni corrections for multiple comparisons were applied.
The mean PTH concentrations for each sample type are displayed in Table 1 and Fig. 1 . Results for specimens collected in EDTA were higher than those for specimens collected in SST tubes irrespective of temperature (P Ͻ0.001). Furthermore, mean PTH values were significantly higher in EDTA RT specimens than EDTA cold (P Ͻ0.001). Time had no significant effect on PTH measurements in EDTA cold specimens (P ϭ 0.172), whereas for Clinical Chemistry 51, No. 5, 2005 
